Center for Neuroscience and Cell Biology, University of Coimbra, Portugal; Institute for Interdisciplinary Research, University of Coimbra, Portugal.
Center for Neuroscience and Cell Biology, University of Coimbra, Portugal; Institute for Interdisciplinary Research, University of Coimbra, Portugal.
Pharmacol Res. 2020 Sep;159:104977. doi: 10.1016/j.phrs.2020.104977. Epub 2020 Jun 3.
Non-healing diabetic foot ulcers (DFUs) are a serious complication in diabetic patients. Their incidence has increased in recent years. Although there are several treatments for DFUs, they are often not effective enough to avoid amputation. Protein tyrosine phosphatase 1B (PTP1B) is expressed in most tissues and is a negative regulator of important metabolic pathways. PTP1B is overexpressed in tissues under diabetic conditions. Recently, PTP1B inhibition has been found to enhance wound healing. PTP1B inhibition decreases inflammation and bacterial infection at the wound site and promotes angiogenesis and tissue regeneration, thereby facilitating diabetic wound healing. In summary, the pharmacological modulation of PTP1B activity may help treat DFUs, suggesting that PTP1B inhibition is an outstanding therapeutic target.
非愈合性糖尿病足溃疡（DFUs）是糖尿病患者的一种严重并发症。近年来，其发病率有所上升。尽管有几种治疗 DFUs 的方法，但它们往往不够有效，无法避免截肢。蛋白酪氨酸磷酸酶 1B（PTP1B）在大多数组织中表达，是重要代谢途径的负调节剂。在糖尿病条件下，PTP1B 在组织中过度表达。最近，发现抑制 PTP1B 可增强伤口愈合。PTP1B 抑制可减少伤口部位的炎症和细菌感染，并促进血管生成和组织再生，从而促进糖尿病伤口愈合。总之，PTP1B 活性的药物调节可能有助于治疗 DFUs，这表明抑制 PTP1B 是一个突出的治疗靶点。
